Recurrence clinical trials
The registry lists 4,274 studies for Recurrence across more than 10 countries. 985 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-25.
Status
- Completed
- 1,927
- Recruiting
- 713
- Status unknown
- 533
- Terminated
- 395
- Not yet recruiting
- 247
- Active, not recruiting
- 238
Phase
- Phase 2
- 1,575
- Phase 1
- 1,085
- Phase 3
- 395
- Phase 4
- 144
- Early Phase 1
- 82
Where
- United States
- 1,866
- China
- 751
- France
- 326
- Canada
- 298
- Italy
- 220
- Spain
- 208
Who runs them
National Cancer Institute (NCI) (475) · M.D. Anderson Cancer Center (74) · Fred Hutchinson Cancer Center (68) · City of Hope Medical Center (43) · Sun Yat-sen University (41) · Memorial Sloan Kettering Cancer Center (40) · Mayo Clinic (38) · Gynecologic Oncology Group (31)
Studies
Recruiting first, then most recently updated. Showing 50 of 4,274 — search for more.
- Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 InhibitorNot yet recruitingNCT07796373Phase 21 country
- Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)RecruitingNCT06788964Phase 21 country
- CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid LeukemiaNot yet recruitingNCT07841002Phase 11 country
- A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaRecruitingNCT03460977Phase 18 countries
- Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38.Not yet recruitingNCT07842445Phase 1
- Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)RecruitingNCT07297979Phase 12 countries
- Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP TrialNot yet recruitingNCT07840456Phase 22 countries
- A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsRecruitingNCT07277413Phase 11 country
- IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)RecruitingNCT07104032Phase 37 countries
- Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory DiseaseRecruitingNCT07509034Phase 11 country
- A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or UbamatamabRecruitingNCT04590326Phase 1/25 countries
- Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin LymphomaRecruitingNCT03618550Phase 21 country
- Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaRecruitingNCT02974647Phase 21 country
- A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has SpreadRecruitingNCT07543055Phase 11 country
- Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent GlioblastomaRecruitingNCT07416188Phase 1/21 country
- Treatment Selection by 3D Bioprinting Liver Model to Prevent Liver Cancer RecurrenceRecruitingNCT078397671 country
- Prognosis and Therapeutic Implications in Molecular High-Risk Non-Myoinvasive Endometrial CancerRecruitingNCT078382071 country
- Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular CarcinomaRecruitingNCT078400921 country
- Phase 1 Dose Escalation Study of RXIM002 in Autoimmune CytopeniasNot yet recruitingNCT07765966Phase 1
- Study of ACR-2316 in Specific Advanced Solid TumorsRecruitingNCT06667141Phase 1/21 country
- A Study of ZEN003694 in People With Squamous Cell Lung CancerRecruitingNCT05607108Phase 21 country
- A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07116616Phase 1/21 country
- A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered GliomaRecruitingNCT06610682Early Phase 11 country
- MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)RecruitingNCT06534437Phase 24 countries
- RVU120 Rollover StudyEnrolling by invitationNCT06987058Phase 22 countries
- Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AMLRecruitingNCT06786533Phase 11 country
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003RecruitingNCT07623798Phase 31 country
- Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell TherapyRecruitingNCT07341191Phase 21 country
- Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCCRecruitingNCT06096038Phase 11 country
- A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical CancerRecruitingNCT05798819Phase 31 country
- A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)RecruitingNCT06173518Phase 13 countries
- ELISA in Relapsed/Refractory MMRecruitingNCT06832865Phase 21 country
- huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular LymphomaRecruitingNCT07343934Phase 11 country
- A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian CancerRecruitingNCT07822646Phase 31 country
- Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLCNot yet recruitingNCT07819591Phase 21 country
- Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHLRecruitingNCT05554939Phase 1/21 country
- Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory LymphomaRecruitingNCT05798897Phase 11 country
- Study of Out of Specification for TisagenlecleucelRecruitingNCT04094311Phase 32 countries
- A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)RecruitingNCT06615479Phase 331 countries
- CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell LymphomasEnrolling by invitationNCT07168486Phase 11 country
- Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06297226Phase 24 countries
- UCD19 CarT in Treatment of Pediatric B-ALL and B-NHLRecruitingNCT04544592Phase 1/21 country
- Post-ablation Alcohol Impacts Arrhythmia Recurrence, Quality of Life and Cognition in AFRecruitingNCT05510167Not applicable1 country
- Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early RelapseRecruitingNCT06827860Phase 21 country
- Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDSRecruitingNCT06846606Phase 11 country
- Iadademstat + SBRT With Atezo in ES-SCLCRecruitingNCT07113691Phase 11 country
- A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesRecruitingNCT06634589Phase 1/28 countries
- Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHLRecruitingNCT06526793Phase 216 countries
- Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHLRecruitingNCT06806033Phase 27 countries
- Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS TumorsRecruitingNCT01356290Phase 28 countries